Docetaxel therapy for advanced hepatocellular carcinoma developed in healthy liver: Report of three cases

Journal of Chemotherapy

Volumn 20, Issue 4, 2008, Pages 518-520

  Romano, O ^a   Truant, S ^a   Sergent Baudson, G ^a   Comet, B ^a   Pruvot, F R ^a   Hebbar, Mohamed ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; Docetaxel; Hepatocellular carcinoma

Indexed keywords

DOCETAXEL; DOXORUBICIN; IODINATED POPPYSEED OIL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; SENSORY NEUROPATHY;

EID: 52249089044     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.4.518     Document Type: Article

References (20)

1. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5 (1): 87-107.
2. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005; 11 (47): 7391-400.
3. Hebbar M, Ernst O, Cattan S et al. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 2006; 70 (2): 154-158.
4. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3): 205-216.
5. Olweny CL, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK. Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 1980; 46 (12): 2717-2722.
6. Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975; 36 (4): 1250-1257.
7. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40 (3): 225-235.
8. O'Reilly EM, Stuart KE, Sanz-Altamira PM et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001; 91 (1): 101-105.
9. Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Macdonald JS. Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs 1997; 15 (3): 257-260.
10. Ulrich-Pur H, Kornek GV, Fiebiger W, Schull B, Raderer M, Scheithauer W. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001; 60 (4): 313-315.
11. Lencioni M, Falcone A, Allegrini G et al. Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. Oncology 2000; 59 (3): 204-209.
12. Chao Y, Chan WK, Birkhofer MJ et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998; 78 (1): 34-39.
13. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000; 89 (5): 983-994.
14. Zhang H, Ozaki I, Mizuta T et al. Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 2002; 95 (4): 896-906.
15. Geng CX, Zeng ZC, Wang JY. Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol 2003; 9 (4): 696-700.
16. Sutter AP, Maaser K, Grabowski P et al. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J Hepatol 2004; 41 (5): 799-807.
17. Ishikawa T, Ichida T, Yokoyama J, Matsuda Y, Watanabe T, Asakura H. Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy. J Gastroenterol Hepatol 2004; 19 (12): 1423-1426.
18. Ryan DP, Lynch TJ, Grossbard ML et al. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer 2000; 88 (1): 180-185.
19. Gornet JM, Azoulay D, Duclos-Vallee JC, Goldwasser F. Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. Anticancer Drugs 2000; 11 (8): 649-652.
20. Llovet J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma: Results of a Phase III randomized placebo-controlled trial (SHARP trial). Proceedings from the 2007 annual meeting of the American Society of Clinical Oncology. Late-breaking Abstract (LBA) #1